Literature DB >> 17916162

Identification of an anti-idiotypic antibody that defines a B-cell subset(s) producing xenoantibodies in primates.

Jacqueline Fischer-Lougheed1, Clare Gregory, Zena White, Irina Shulkin, Mirja Gunthart, Mary Kearns-Jonker.   

Abstract

Synthetic anti-idiotypic antibodies represent a potentially valuable tool for the isolation and characterization of B cells that produce xenoantibodies. An anti-idiotypic antibody that binds to a subset of B cells producing antibodies encoded by the variable-region heavy chain 3 (V(H)3) germline genes DP35 [immunoglobulin variable-region heavy chain 3-11 (IGHV3-11)], DP-53 and DP-54 plus a small number of V(H)4 gene-encoded antibodies in humans has recently been identified. These germline progenitors also encode xenoantibodies in humans. We tested whether the small, clearly defined group of B cells identified with this anti-idiotypic antibody produce xenoantibodies in non-human primates mounting active immune responses to porcine xenografts. Peripheral blood B cells were sorted by flow cytometry on the basis of phenotype, and cDNA libraries were prepared from each of these sorted groups of cells. Immunoglobulin V(H) gene libraries were prepared from the sorted cells, and the V(H) genes expressed in each of the sorted groups were identified by nucleic acid sequencing. Our results indicate that xenoantibody-producing peripheral blood B cells, defined on the basis of binding to fluorescein isothiocyanate (FITC)-conjugated galactose alpha(1,3) galactose-bovine serum albumin (Gal-BSA) and the anti-idiotypic antibody 2G10, used the IGHV3-11 germline gene to encode xenoantibodies and were phenotypically CD11b+ (Mac-1+) and CD5-. This novel reagent may be used in numerous applications including definition of xenoantibody-producing B-cell subsets in humans and non-human primates and immunosuppression by depletion of B cells producing anti-Gal xenoantibodies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916162      PMCID: PMC2433327          DOI: 10.1111/j.1365-2567.2007.02704.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  39 in total

1.  Differences between synthetic oligosaccharide immunoabsorbents in depletion capacity for xenoreactive anti-Galalpha1-3Gal antibodies from human serum.

Authors:  B Gerber; C Tinguely; N V Bovin; R Rieben; U E Nydegger
Journal:  Xenotransplantation       Date:  2001-05       Impact factor: 3.907

2.  Injection of porcine anti-idiotypic antibodies to primate anti-Gal antibodies leads to active inhibition of serum cytotoxicity in a baboon.

Authors:  L Bühler; S Treter; I McMorrow; F A Neethling; I Alwayn; M Awwad; A Thall; D K Cooper; C LeGuern; D H Sachs
Journal:  Transplant Proc       Date:  2000-08       Impact factor: 1.066

3.  Specific depletion of preformed IgM natural antibodies by administration of anti-mu monoclonal antibody suppresses hyperacute rejection of pig to baboon renal xenografts.

Authors:  J P Dehoux; S Hori; S Talpe; H Bazin; D Latinne; M P Soares; P Gianello
Journal:  Transplantation       Date:  2000-09-27       Impact factor: 4.939

4.  Multivalent Galalpha1,3Gal-substitution makes recombinant mucin-immunoglobulins efficient absorbers of anti-pig antibodies.

Authors:  Jining Liu; Andrej Weintraub; Jan Holgersson
Journal:  Xenotransplantation       Date:  2003-03       Impact factor: 3.907

5.  Mac-1-negative B-1b phenotype of natural antibody-producing cells, including those responding to Gal alpha 1,3Gal epitopes in alpha 1,3-galactosyltransferase-deficient mice.

Authors:  H Ohdan; K G Swenson; H S Kruger Gray; Y G Yang; Y Xu; A D Thall; M Sykes
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

6.  Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning.

Authors:  Liangxue Lai; Donna Kolber-Simonds; Kwang-Wook Park; Hee-Tae Cheong; Julia L Greenstein; Gi-Sun Im; Melissa Samuel; Aaron Bonk; August Rieke; Billy N Day; Clifton N Murphy; David B Carter; Robert J Hawley; Randall S Prather
Journal:  Science       Date:  2002-01-03       Impact factor: 47.728

7.  Modulation of the in vivo primate anti-Gal response through administration of anti-idiotypic antibodies.

Authors:  Isabel M McMorrow; Leo Buhler; Sarah Treter; Francisca A Neethling; Ian P J Alwayn; Christopher A Comrack; Hiroshi Kitamura; Michel Awwad; Harout DerSimonian; David K C Cooper; David H Sachs; Christian LeGuern
Journal:  Xenotransplantation       Date:  2002-03       Impact factor: 3.907

8.  Pig cells that lack the gene for alpha1-3 galactosyltransferase express low levels of the gal antigen.

Authors:  Ajay Sharma; Bashoo Naziruddin; Cunqi Cui; Michael J Martin; Hui Xu; Hua Wan; Ying Lei; Caren Harrison; Jessie Yin; Jeannine Okabe; Christine Mathews; Aileen Stark; Connie S Adams; Jeffrey Houtz; Barry S Wiseman; Guerard W Byrne; John S Logan
Journal:  Transplantation       Date:  2003-02-27       Impact factor: 4.939

9.  Production of alpha 1,3-galactosyltransferase-deficient pigs.

Authors:  Carol J Phelps; Chihiro Koike; Todd D Vaught; Jeremy Boone; Kevin D Wells; Shu-Hung Chen; Suyapa Ball; Susan M Specht; Irina A Polejaeva; Jeff A Monahan; Pete M Jobst; Sugandha B Sharma; Ashley E Lamborn; Amy S Garst; Marilyn Moore; Anthony J Demetris; William A Rudert; Rita Bottino; Suzanne Bertera; Massimo Trucco; Thomas E Starzl; Yifan Dai; David L Ayares
Journal:  Science       Date:  2002-12-19       Impact factor: 47.728

10.  Efficient generation of alpha(1,3) galactosyltransferase knockout porcine fetal fibroblasts for nuclear transfer.

Authors:  Sharon J Harrison; Angelo Guidolin; Renate Faast; Lesley A Crocker; Chris Giannakis; Anthony J F D'Apice; Mark B Nottle; Ian Lyons
Journal:  Transgenic Res       Date:  2002-04       Impact factor: 2.788

View more
  2 in total

1.  The anti-non-gal xenoantibody response to xenoantigens on gal knockout pig cells is encoded by a restricted number of germline progenitors.

Authors:  K Kiernan; I Harnden; M Gunthart; C Gregory; J Meisner; M Kearns-Jonker
Journal:  Am J Transplant       Date:  2008-07-28       Impact factor: 8.086

Review 2.  Xenotransplantation: immunological hurdles and progress toward tolerance.

Authors:  Adam Griesemer; Kazuhiko Yamada; Megan Sykes
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.